Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2-vc0101 ADC PF-06804103

A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER2-vcAur0101 ADC PF-06804103
anti-NG-HER2 ADC PF-06804103
anti-NG-Her2-vc0101 ADC PF-06804103
antibody-drug conjugate PF-06804103
Code name:PF 06804103
PF-06804103
PF06804103
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search